Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Revolution Medicines Doubles Stock Offering Target to $2 Billion Following Pancreatic Cancer Breakthrough [TheStreet.com]
Why Revolution Medicines (RVMD) Still Looks Like a Prime Takeover Target After Daraxonrasib Data [Yahoo! Finance]
Revolution Medicines prices $2B in concurrent stock, notes offerings [Seeking Alpha]
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes [Yahoo! Finance]